<div id="readability-page-1"><div id="parent_top_div">India's drug regulator on Friday ordered state authorities to ensure all pharmaceutical factories comply with international manufacturing standards by January, rejecting industry pleas for more time after toxic cough syrup was linked to additional child deaths since September. The government had directed drugmakers in late 2023 to upgrade plants to World Health Organization-recommended norms, including measures to prevent cross-contamination and enable batch testing. The move followed global outrage after India-made cough syrups were tied to the deaths of more than 140 children in Africa and Central Asia, tarnishing the country's reputation as the &#34;pharmacy of the world.&#34; Large pharmaceutical firms met a June 2024 deadline, while smaller manufacturers were given until December 2025 as part of an earlier extension. Industry groups had sought further extensions, warning that compliance costs could bankrupt small businesses. But the deaths of 24 children in central India linked to contaminated syrup prompted authorities to hold firm. The Central Drugs Standard Control Organisation said in a notice, seen by Reuters, that the revised standards under &#34;Schedule M&#34; will apply to all manufacturers from January 1, and directed state regulators to begin inspections. &#34;In case any manufacturing unit is found non-complying with the requirements of revised Schedule M during inspections, strict action shall be initiated,&#34; the notice, signed by Drugs Controller General Rajeev Singh Raghuvanshi, said. Firms that do not fall under the extension criteria should be inspected immediately, the notice said. He asked states to treat the matter as a &#34;top priority&#34;. Raghuvanshi's office did not immediately respond to a request for a comment. Reuters reported exclusively on October 17 that no extension would be granted. However, an association representing small- and medium-sized drugmakers warned the mandate could shutter many factories, causing job losses and pushing up medicine prices. &#34;What good is quality if there is no affordability?&#34; said Jagdeep Singh, secretary of the SME Pharma Industries Confederation. </div></div>

印度药品监管机构已要求所有制药厂在一月份之前遵守国际生产标准，此举是由于与有毒咳嗽糖浆相关的 140 多名儿童死亡事件。中央药品标准控制组织强调，将开始严格检查，不合规的制造商将面临严厉后果。虽然大型企业已满足早期截止日期，但小型制造商表示，合规成本可能导致破产和药品价格上涨。政府已拒绝进一步延期的请求，优先考虑药品生产的安全和质量

由于咳嗽糖浆致死事件，CDSCO 要求制药商在一月前达到全球标准